CCME Global

Which are the latest news on CCME Global?

Why is Genesis IBRC India Ltd falling/rising?

As of 03-Jun, the stock price of CCME Global Ltd is declining, currently at 111.10, down 4.96%. This drop is attributed to decreased investor participation and erratic trading patterns, despite being above longer-term moving averages.

As of 03-Jun, the stock price of CCME Global Ltd is falling, as indicated by a current price of 111.10, which reflects a change of -5.8 or -4.96%. This decline is evident in the stock's performance today, where it underperformed the sector by -4.85%. The stock opened with a loss of -4.96% and has not shown any range in trading, remaining at the same price throughout the day. Additionally, the stock has experienced erratic trading, not trading on 5 out of the last 20 days, which may contribute to its volatility and declining price. <BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by -98.41% compared to the 5-day average, indicating a lack of interest from investors. Although the stock is trading higher than its 20-day, 50-day, 100-day, and 200-day moving averages, it is lower than the 5-day moving average, suggesting a recent downward trend. Overall, these factors collectively explain the current decline in the stock price of CCME Global Ltd.

Should I buy, sell or hold Genesis IBRC India Ltd?

When is the next results date for Genesis IBRC India Ltd?

The next results date for Genesis IBRC India Ltd is 14 February 2026.

The next results date for Genesis IBRC India Ltd is scheduled for 14 February 2026.

How has been the historical performance of Genesis IBRC?

Genesis IBRC reported a total operating income of 4.34 Cr for the year ending March 2018, resulting in a profit after tax of -0.03 Cr and an earnings per share of -0.03. The company had total liabilities and assets of 12.29 Cr, with no cash flow activity during the period.

Answer:<BR>The historical performance of Genesis IBRC for the year ending March 2018 shows a total operating income of 4.34 Cr, with net sales contributing 4.33 Cr. The total expenditure, excluding depreciation, was 4.16 Cr, leading to an operating profit (PBDIT) of 0.18 Cr. After accounting for interest expenses of 0.03 Cr and depreciation of 0.09 Cr, the profit before tax was recorded at 0.06 Cr. However, the company faced a tax expense of 0.10 Cr, resulting in a profit after tax of -0.03 Cr, which also reflects in the consolidated net profit. The earnings per share (EPS) stood at -0.03, indicating a loss per share. The operating profit margin was 4.2%, while the profit after tax margin was -0.78%. The company had a total liability of 12.29 Cr, with shareholder's funds amounting to 9.61 Cr and total assets also at 12.29 Cr. The cash flow results indicated no cash inflow or outflow during the period.<BR><BR>Breakdown:<BR>Genesis IBRC's financial results for March 2018 reveal a total operating income of 4.34 Cr, primarily driven by net sales of 4.33 Cr. The company managed to maintain a low total expenditure of 4.16 Cr, resulting in an operating profit of 0.18 Cr. However, the profit before tax was only 0.06 Cr, which turned negative after accounting for tax expenses, leading to a profit after tax of -0.03 Cr. This loss per share is reflected in the earnings per share of -0.03. The company's operating profit margin was 4.2%, but the profit after tax margin was negative at -0.78%. On the balance sheet, total liabilities matched total assets at 12.29 Cr, with shareholder's funds at 9.61 Cr. The cash flow statement indicated no activity, with a closing cash balance of 0.00 Cr.

Is Genesis IBRC overvalued or undervalued?

As of September 5, 2025, Genesis IBRC is considered very expensive and overvalued, with high valuation ratios compared to peers and a PEG ratio of 0.00 indicating no expected growth, despite a strong historical return of 281.47% over three years.

As of 5 September 2025, the valuation grade for Genesis IBRC has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios reveal a PE ratio of 14.83, an EV to EBITDA of 14.79, and a Price to Book Value of 10.33, which are notably high compared to industry peers.<BR><BR>In comparison to its peers, Genesis IBRC's valuation metrics are considerably less favorable. For instance, Supreme Industries has a PE ratio of 65.23, while Astral's PE stands at 80.78, both indicating a premium valuation. Additionally, the PEG ratio for Genesis is reported at 0.00, which suggests no expected growth, further reinforcing the overvaluation stance. Despite a strong performance with a 281.47% return over three years, the current valuation metrics suggest that investors should approach Genesis IBRC with caution.

How big is Genesis IBRC?

As of 24th July, Genesis IBRC India Ltd has a market capitalization of 35.00 Cr, classifying it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit loss of 3.75 Cr in the latest four quarters. The latest balance sheet from March 2018 shows Shareholder's Funds at 9.61 Cr and Total Assets at 12.29 Cr.

As of 24th July, Genesis IBRC India Ltd has a market capitalization of 35.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit loss of 3.75 Cr.<BR><BR>The latest annual period for the balance sheet is March 2018, with Shareholder's Funds reported at 9.61 Cr and Total Assets at 12.29 Cr.

What does Genesis IBRC do?

Genesis IBRC India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 1992 and formerly known as Fine Plast Polymers Ltd. As of March 2025, it reported net sales and a net profit of 0 Cr, with a market cap of INR 29 Cr.

Overview: <BR>Genesis IBRC India Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in October 1992 as Fine Plast Polymers Ltd. It underwent several name changes, first to SSK Lifestyles Ltd in October 2014, and then to Genesis IBRC India Ltd in January 2018. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 223 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: -0.57% <BR>Price-to-Book: 3.28 <BR><BR>Contact Details: <BR>Address: Sy Nos 241/2 & 389/2 Dwaraka, Denduluru Village & Mandal West Godavari Andhra Pradesh : 534432 <BR>Email: info@ssklifstyles.com <BR>Website: http://www.genesisbrc.com

Who are the top shareholders of the Genesis IBRC?

The top shareholders of Genesis IBRC are Diligent Industries Limited with 23.08%, and promoter Arun Kumar P with 4.49%. Individual investors collectively hold 49.31% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genesis IBRC include Diligent Industries Limited, which holds the highest public shareholding at 23.08%. Additionally, Arun Kumar P is the promoter with the highest individual holding at 4.49%. Individual investors collectively hold 49.31% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Who are the peers of the Genesis IBRC?

Peers of Genesis IBRC include Veerhealth Care, Guj. Terce Labs., Shree Ganesh Bio, Vineet Laborator, Phaarmasia, Ishita Drugs, Zenith Health, Desh Rakshak, and Vilin Bio Med, with varying management and growth risks. Desh Rakshak has the highest 1-year return at 415.29%, while Vineet Laborator has the lowest at -49.62%.

Peers: The peers of Genesis IBRC are Veerhealth Care, Guj. Terce Labs., Shree Ganesh Bio, Vineet Laborator, Phaarmasia, Ishita Drugs, Zenith Health, Desh Rakshak, and Vilin Bio Med.<BR><BR>Quality Snapshot: Below Average management risk is observed at Veerhealth Care, Guj. Terce Labs., Shree Ganesh Bio, Vineet Laborator, Phaarmasia, Ishita Drugs, Zenith Health, Desh Rakshak, and Vilin Bio Med, while Average management risk is found at Vineet Laborator. Growth ratings show Below Average for Veerhealth Care, Shree Ganesh Bio, Phaarmasia, and the rest, while Average growth is noted at Guj. Terce Labs. Capital Structure is rated Good for Veerhealth Care, Shree Ganesh Bio, Ishita Drugs, and Zenith Health, while Below Average is seen at Guj. Terce Labs., Vineet Laborator, Phaarmasia, Desh Rakshak, and Vilin Bio Med.<BR><BR>Return Snapshot: Desh Rakshak has the highest 1-year return at 415.29%, while Vineet Laborator has the lowest at -49.62%. Genesis IBRC's own 1-year return of 54.90% is significantly higher than Vineet Laborator's. Additionally, several peers, including Guj. Terce Labs., Shree Ganesh Bio, Vineet Laborator, Phaarmasia, Ishita Drugs, Zenith Health, and Vilin Bio Med, have negative six-month returns.

Who are in the management team of Genesis IBRC?

As of March 2022, the management team of Genesis IBRC includes Vanitha Nagulavari (Director), Mohammed Baba (Independent Director), Prasada Rao Kalluri (Independent Director), Balakrishna Koppula (Whole-time Director), and M V R L Subrahmanyeswara Rao (Company Secretary & Compliance Officer). Each member contributes to the company's governance and compliance.

As of March 2022, the management team of Genesis IBRC includes the following individuals:<BR><BR>1. Vanitha Nagulavari - Director<BR>2. Mohammed Baba - Independent Director<BR>3. Prasada Rao Kalluri - Independent Director<BR>4. Balakrishna Koppula - Whole-time Director<BR>5. M V R L Subrahmanyeswara Rao - Company Secretary & Compliance Officer<BR><BR>Each member plays a significant role in the governance and compliance of the company.